I am a leading expert in human systems biology approaches for chemical safety assessment. My research advances the integration of physiologically-based pharmacokinetic modeling, and quantitative in vitro to in vivo extrapolation to translate results from non-animal and human cell-based toxicity studies into reliable human exposure safety estimates for health risk assessment.

I have earned my PhD in Public Health with a specialization in Toxicology from the University of Montreal, where I investigated the quantitative relationships between benzo[a]pyrene (BaP) exposure, biomarker evolution over time, and early biological changes. I completed a postdoctoral fellowship at Health Canada's Computational Toxicology Laboratory under the supervision of Dr. Andy Nong. My research has been supported by the Natural Sciences and Engineering Research Council of Canada (NSERC), with a focus on applying pharmacokinetic models and high-throughput screening data to assess chemical hazards. A key aspect of my work involved combining in vitro to in vivo extrapolation methods with biomonitoring studies to provide actionable insights for public health decision-making.

At ESQlabs, I lead and collaborate with multidisciplinary teams to implement Next Generation Risk Assessment (NGRA) projects, while providing specialized consultation in physiologically based biokinetic modeling (PBK) and quantitative in vitro to in vivo extrapolation (QIVIVE) across various company projects and programs. I lead global regulatory engagement in NGRA initiatives, positioning ESQlabs as a credible regulatory partner in the US. My leadership focuses on translating mechanistic approaches into impactful applications while driving the expansion of the NGRA market.